Tumor‑infiltrating CD8(+) T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma

Atezolizumab plus bevacizumab and lenvatinib are approved frontline therapies for advanced hepatocellular carcinoma (HCC). Patients with advanced HCC continue to have a poor prognosis despite these therapeutic choices. Previous studies have reported CD8(+) tumor-infiltrating lymphocytes (TILs) as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwano, Akifumi, Yada, Masayoshi, Miyazaki, Yoshiko, Tanaka, Kosuke, Kurosaka, Kazuki, Ohishi, Yoshihiro, Masumoto, Akihide, Motomura, Kenta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189850/
https://www.ncbi.nlm.nih.gov/pubmed/37205921
http://dx.doi.org/10.3892/ol.2023.13845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189850/
https://www.ncbi.nlm.nih.gov/pubmed/37205921
http://dx.doi.org/10.3892/ol.2023.13845

Ejemplares similares